Market Movement
Novartis (NVS) closed the most recent trading session at $94.41, showcasing a decline of -1.52% from the prior day’s close. This descent trailed behind the daily losses experienced by the S&P 500, which fell by 0.72%. Concurrently, the Dow saw a downturn of 1%, while the Nasdaq, known for its tech-heavy focus, depreciated by 0.95%.
Recent Performance and Projections
Over the past month, Novartis shares have dwindled by 5.98%, underperforming against the Medical sector’s 0.03% loss and the S&P 500’s 2.16% gain during this period.
As the investment community eagerly awaits Novartis’s earnings report, analysts anticipate an EPS of $1.72, marking a 0.58% increase from the same quarter last year. Furthermore, the consensus estimate for revenue is $11.41 billion, suggesting an 11.9% dip compared to the previous year’s quarter.
Looking ahead to the fiscal year, Zacks Consensus Estimates project earnings of $7.17 per share and revenue of $47.32 billion, reflecting changes of +3.91% and -4.95%, respectively, from the preceding year.
Analyst Estimates and Ratings
Analysts’ recent adjustments to estimates for Novartis offer insight into evolving business trends. Positive revisions in estimates bode well for the company’s future. This interplay between estimates and stock performance led to the creation of the Zacks Rank system, which spans from #1 (Strong Buy) to #5 (Strong Sell). Notably, #1 ranked stocks have historically delivered an average annual return of +25%.
Recent data reveals that Novartis currently holds a Zacks Rank of #4 (Sell), with a 0.06% decrease in the Zacks Consensus EPS estimate over the last month.
Valuation and Industry Analysis
From a valuation perspective, Novartis trades at a Forward P/E ratio of 13.37, lower than the industry’s average of 14.81. The company’s PEG ratio stands at 1.49, with the Large Cap Pharmaceuticals industry averaging 1.73.
Within the Medical sector, the Large Cap Pharmaceuticals industry, including Novartis, ranks in the bottom 14% with a Zacks Industry Rank of 218. Industries in the top 50% have historically outperformed the bottom half by a notable margin.
Insight and Recommendations
Intrigued investors are encouraged to track these critical metrics using Zacks.com for valuable insights as trading unfolds.
Opportunities for Growth
Zacks experts have pinpointed a hidden gem poised for significant growth amidst the market turbulence. This promising chemical company, with soaring demand, robust earnings estimates for 2022, and share repurchase plans, offers an enticing opportunity.
Comparable to previous success stories like Boston Beer Company and NVIDIA, this under-the-radar stock could be the next big winner for investors seeking substantial returns.
Conclusion
As Novartis navigates through market challenges and economic uncertainties, investors must carefully weigh the available information and projections. By staying informed and leveraging tools like Zacks Rank, they can make informed decisions tailored to their investment strategies and risk appetite.
Disclaimer: The insights presented here are the author’s opinion and do not necessarily reflect the views of Nasdaq, Inc.
